Zobrazeno 1 - 10
of 100
pro vyhledávání: '"Carmela Pisano"'
Autor:
Francesca Arezzo, Gaia Giannone, Daniele Castaldo, Giulia Scotto, Valentina Tuninetti, Margherita Turinetto, Michele Bartoletti, Serafina Mammoliti, Grazia Artioli, Giorgia Mangili, Vanda Salutari, Domenica Lorusso, Gennaro Cormio, Vera Loizzi, Claudio Zamagni, Antonella Savarese, Massimo Di Maio, Graziana Ronzino, Carmela Pisano, Sandro Pignata, Giorgio Valabrega
Publikováno v:
Frontiers in Oncology, Vol 13 (2024)
Externí odkaz:
https://doaj.org/article/dcf619c78545464a823c5d3ef4cc8cc3
Autor:
Anna Passarelli, Carmela Pisano, Elisabetta Coppola, Jole Ventriglia, Sabrina Chiara Cecere, Marilena Di Napoli, Luciano Carideo, Secondo Lastoria, Sandro Pignata
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
Cervical cancer (CC) is the second most commonly diagnosed cancer and the third leading cause of cancer death among females. The options of treatment for recurrent/advanced CC are limited and patients experiencing recurrence after first line platinum
Externí odkaz:
https://doaj.org/article/13637c934c6e47e7b047a0176efec119
Autor:
Francesca Arezzo, Gaia Giannone, Daniele Castaldo, Giulia Scotto, Valentina Tuninetti, Margherita Turinetto, Michele Bartoletti, Serafina Mammoliti, Grazia Artioli, Giorgia Mangili, Vanda Salutari, Domenica Lorusso, Gennaro Cormio, Vera Loizzi, Claudio Zamagni, Antonella Savarese, Massimo Di Maio, Graziana Ronzino, Carmela Pisano, Sandro Pignata, Giorgio Valabrega
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
IntroductionEndometrial cancer (EC) represents 3.4% of all newly diagnosed cancer cases and is responsible for 2.1% of all cancer-related deaths. Approximately 10%–15% of women with EC are diagnosed with advanced-stage disease, resulting in a repor
Externí odkaz:
https://doaj.org/article/f5bb38ac79f64befb91e18a43fc5f3ed
Autor:
Anna Passarelli, Jole Ventriglia, Carmela Pisano, Sabrina Chiara Cecere, Marilena Di Napoli, Sabrina Rossetti, Rosa Tambaro, Luca Tarotto, Francesco Fiore, Alberto Farolfi, Michele Bartoletti, Sandro Pignata
Publikováno v:
Frontiers in Oncology, Vol 12 (2023)
Endometrial cancer (EC) is the most common gynecologic cancer in Europe and its prevalence is increasing. EC includes a biological and clinical heterogeneous group of tumors, usually classified as type I (endometrioid) or type II (non-endometrioid) b
Externí odkaz:
https://doaj.org/article/195e07dbdcf3463fa5306ed4d9466769
Autor:
Anna Passarelli, Carmela Pisano, Sabrina Chiara Cecere, Marilena Di Napoli, Sabrina Rossetti, Rosa Tambaro, Jole Ventriglia, Federica Gherardi, Eva Iannacone, Sergio Setola Venanzio, Francesco Fiore, Michele Bartoletti, Giosuè Scognamiglio, Daniela Califano, Sandro Pignata
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Immunotherapy is acquiring a primary role in treating endometrial cancer (EC) with a relevant benefit for many patients. Regardless, patients progressing during immunotherapy or those who are resistant represent an unmet need. The mechanisms of immun
Externí odkaz:
https://doaj.org/article/a566ec8355c14cb985e3d260165dc78e
Autor:
Gaia Giannone, Daniele Castaldo, Valentina Tuninetti, Giulia Scotto, Margherita Turinetto, Anna Amela Valsecchi, Michele Bartoletti, Serafina Mammoliti, Grazia Artioli, Giorgia Mangili, Vanda Salutari, Domenica Lorusso, Gennaro Cormio, Claudio Zamagni, Antonella Savarese, Massimo Di Maio, Graziana Ronzino, Carmela Pisano, Sandro Pignata, Giorgio Valabrega
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BackgroundEndometrial cancer (EC) therapeutic and diagnostic approaches have been changed by the development of a new prognostic molecular classification, the introduction of dostarlimab in microsatellite instability (MSI) high pre-treated advanced E
Externí odkaz:
https://doaj.org/article/b9a686d498904e73bedff9d6707f8bb3
Autor:
Marina Fabbi, Delfina Costa, Daniela Russo, Laura Arenare, Gabriele Gaggero, Simona Signoriello, Giovanni Scambia, Carmela Pisano, Nicoletta Colombo, Nunzia Simona Losito, Gilberto Filaci, Anna Spina, Daniela Califano, Giosuè Scognamiglio, Angiolo Gadducci, Delia Mezzanzanica, Marina Bagnoli, Silvano Ferrini, Vincenzo Canzonieri, Paolo Chiodini, Francesco Perrone, Sandro Pignata
Publikováno v:
Diagnostics, Vol 12, Iss 9, p 2118 (2022)
To find prognostic factors for advanced ovarian cancer patients undergoing first-line therapy with carboplatin, paclitaxel and bevacizumab, we investigated the expression of a disintegrin and metalloprotease 17 (ADAM17) in cancer tissues. ADAM17 has
Externí odkaz:
https://doaj.org/article/3475ee8b2aad49adbddeb11eea2ac3be
Publikováno v:
Therapeutics and Clinical Risk Management, Vol 2009, Iss default, Pp 421-426 (2009)
Carmela Pisano, Giovanni S Bruni, Gaetano Facchini, Claudia Marchetti, Sandro PignataOncologia Medica, Dipartimento Uro-Ginecologico, Istituto Nazionale Tumori, Napoli, ItalyAbstract: Epidemiologic analysis reveals that the mortality rate from ovaria
Externí odkaz:
https://doaj.org/article/9330e4724c484f6f861d02ebf2d04b61
Autor:
Mansoor R. Mirza, Antonio González‐Martín, Whitney S. Graybill, David M. O’Malley, Lydia Gaba, Oi Wah Stephanie Yap, Eva M. Guerra, Peter G. Rose, Jean‐François Baurain, Sharad A. Ghamande, Hannelore Denys, Emily Prendergast, Carmela Pisano, Philippe Follana, Klaus Baumann, Paula M. Calvert, Jacob Korach, Yong Li, Izabela A. Malinowska, Divya Gupta, Bradley J. Monk
Publikováno v:
CANCER
Background: The PRIMA/ENGOT-OV26/GOG-3012 (NCT02655016) trial was amended to prospectively evaluate the safety and efficacy of an individualized starting dose (ISD) regimen of niraparib for first-line maintenance therapy in patients with newly diagno
Autor:
Sandro Pignata, Giovanni Scambia, Clorinda Schettino, Laura Arenare, Carmela Pisano, Davide Lombardi, Ugo De Giorgi, Claudia Andreetta, Saverio Cinieri, Carmine De Angelis, Domenico Priolo, Claudia Casanova, Marta Rosati, Filippo Greco, Elena Zafarana, Ilaria Schiavetto, Serafina Mammoliti, Sabrina Chiara Cecere, Vanda Salutari, Simona Scalone, Alberto Farolfi, Marilena Di Napoli, Domenica Lorusso, Piera Gargiulo, Daniela Califano, Daniela Russo, Anna Spina, Rossella De Cecio, Paolo Chiodini, Francesco Perrone, Valentina Accinno, Chiara Altavilla, Giovanna Antonelli, Grazia Artioli, Francesco Avola, Bonifacio Barbara, Valentina Barbato, Michele Bartoletti, Simona Bevilacqua, Roberto Bordonaro, Oriana Borghese, Gaetano Buonfanti, Floriana Camarda, Giuliana Canzanella, Vittoria Carbone, Maria Rita Carbone, Giulia Carlo Stella, Chiara Cassani, Fabrizio Castagna, Monica Cattaneo, Margherita Cinefra, Nicoletta Colombo, Serena Corsetti, Monia Dall'Agata, Maria D'Amico, Gennaro Daniele, Elvira De Marino, Giovanni De Matteis, Sabino De Placido, Gabriella Del Bene, Antonia Del Giudice, Francesca Del Monte, Michele Del Sesto, Maddalena Donini, Giuliana Drudi, Gianluca Falcone, Adolfo Favaretto, Giulia Ferrera, Manuela Florio, Valeria Forestieri, Maria Stella Gallo, Ciro Gallo, Francesca Garibaldi, Fabiana Gerevini, Viola Ghizzoni, Maria Olga Giganti, Anna Gimigliano, Elena Giudice, Nicoletta Gnocchi, Adriano Gravina, Stefano Greggi, Maria Laura Iaia, Annalisa Ilardi, Gelsomina Iovine, Gabriella Ippoliti, Giulia Irollo, Ilenia Isidori, Mariateresa Lapresa, Giuseppe Lavenia, Laura Longhitano, Bortot Lucia, Gabriella Luzi, Sara Mariano, Valentina Marino, Giovanna Marrapese, Marilena Martino, Roberta Matocci, Enrica Mazzoni, Daniela Mercuri, Maria Mirto, Giovanna Mollo, Abbondanza Montinaro, Marta Moscatelli, Anna Maria Mosconi, Lucia Musacchio, Nicoletta Nanni, Pamela Natalucci, Milena Sabrina Nicoloso, Michele Orditura, Gabriella Maria Parma, Rodolfo Passalacqua, Michela Pelone, Maria Teresa Perri, Bruno Perrucci, Alessandra Piancastelli, Maria Carmela Piccirillo, Antonio Piccolo, Stefania Rapisardi, Giorgia Ravaglia, Teresa Ribecco, Caterina Ricci, Marianna Roccio, Fiorella Romano, Daniela Sambataro, Alfonso Savio, Ada Sbriglia, Cono Scaffa, Concetta Sergi, Francesca Sgandurra, Roberto Sorio, Stefano Stabile, Gianna Tabaro, Margherita Tambaro, Stefano Tamberi, Angelica Tecchiato, Angela Maria Trujillo, Eleonora Zaccarelli
Publikováno v:
The Lancet Oncology. 24:286-296
Background: Adding immunotherapy to first-line chemotherapy might improve outcomes for patients with advanced or recurrent endometrial cancer. We aimed to compare carboplatin and paclitaxel versus avelumab plus carboplatin and paclitaxel as first-lin